Physician profile
Daniel E Ezekwudo
NPI 1942649769
$4,802.92
in general payments reported to CMS, 2019-2025
42 companies · $1,033 in 2025
The $1,033 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $221 · 2021: $343 · 2022: $449 · 2023: $848 · 2024: $1,650 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,150 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.43 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,782.54 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $275.66 | 2019-2025 | Opdivo |
| Coherus Oncology, INC. | $220.62 | 2020 | |
| Celgene Corporation | $206.37 | 2022-2025 | Pomalyst, Reblozyl, Pomalyst |
| Pfizer INC. | $163.72 | 2022-2025 | |
| Glaxosmithkline, LLC. | $143.75 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Incyte Corporation | $141.64 | 2021-2025 | Niktimvo, Jakafi |
| Astellas Pharma US INC | $136.77 | 2023-2025 | Vyloy, Xtandi |
| Global Blood Therapeutics, INC. | $121.83 | 2021 | |
| Genentech USA, INC. | $118.85 | 2023-2025 | Phesgo, Tecentriq, Alecensa |
| Astrazeneca Pharmaceuticals LP | $112.47 | 2019-2022 | |
| Genzyme Corporation | $104.42 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $97.34 | 2022 | |
| Janssen Biotech, INC. | $82.65 | 2022-2025 | Talvey, Darzalex |
| Merck Sharp & Dohme LLC | $78.56 | 2024-2025 | Keytruda, Keytruda Qlex |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ezekwudo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.